Introduction
Serum PSA is routinely used for prostate cancer screening and is the mainstay of post-treatment surveillance. A detectable or rising PSA level suggests disease recurrence in patients who have undergone curative treatment for prostate cancer, which may lead to diagnostic procedures and salvage therapy. Like many tumor markers, PSA is measured by sandwich immunoassay, in which two antibodies of animal origin designed to recognize different epitopes on PSA are introduced to the patient sample. One of the antibodies (the 'capture' antibody) is usually immobilized on a solid surface, whereas the other antibody (the 'detector' antibody) is tagged with a label that permits signal identification ( Figure 1a ). 1 Rarely, PSA results may become spuriously elevated, secondary to improper specimen collection, processing, or from assay interferences (e.g., cross-reacting molecules such as heterophilic antibodies). 2 There are seven cases reported in the English literature of spuriously elevated PSA results in pre-and post-prostatectomy patients that were found to be due to heterophilic antibody interference and, in some cases, led to unnecessary salvage treatments. [3] [4] [5] [6] [7] [8] [9] Heterophilic antibodies are endogenously produced anti-animal antibodies that can bind to the antibodies used in laboratory assays, including the PSA assay. It has been proposed that they develop secondary to animal exposure, ingestion of animal antigens, or even medical exposure. 1 Falsely elevated results may be obtained if these antibodies cross link the capture and detector antibodies in the absence of the antigen (Figure 1b) .
In response to concern over spurious PSA results, the medical directors of the clinical laboratory at the Mayo Clinic recently reviewed a large series of PSA results and found that approximately 0.4% of patients experienced small, spurious PSA elevations (personal communication). This phenomenon was secondary to interfering heterophilic antibodies, causing PSA values to change from undetectable (o0.1 ng ml À1 ) to low detectable levels (0.1-0.3 ng ml À1 ), and was traced to certain lot numbers of reagent specific to the Beckman Coulter Hybritech PSA assay (Brea, CA, USA). This finding is unique to the literature, as it reflects small PSA changes due to heterophilic antibody interference, as opposed to most published reports that describe larger changes. [3] [4] [5] [6] [7] [8] [9] To evaluate the risk of heterophilic antibody interference in our population, we undertook a quality improvement project at Vanderbilt University Medical Center (VUMC) to study new PSA elevations in patients with previously undetectable results. In phase I, patients with spurious PSA elevations were retrospectively identified to estimate the prevalence of this occurrence and to determine the clinical consequences. Specifically, whether diagnostic evaluation or salvage therapy were unnecessarily utilized in men with a history of prostate cancer. In phase II, we evaluated small PSA elevations prospectively and tested for the presence of interfering heterophilic antibodies.
Materials and methods
In this two-phased quality improvement study, patients were retrospectively (phase I) and prospectively (phase II) identified, based upon search of the laboratory information system for PSA results. Internal review board approval was received for all quality improvement projects performed in the VUMC Core Laboratory.
PSA assay
All PSA testing was performed in the VUMC Core Laboratory. PSA was measured on the Beckman Coulter DxI immunoassay platform (Beckman Coulter). The Access Hybritech assay (Beckman Coulter) is a two-site immunoenzymatic 'sandwich' assay in which both the capture and detector antibodies are mouse monoclonal antibodies. The PSA in the patient sample binds to the immobilized capture antibody while the detector antibody reacts with a different antigenic site on PSA, thus creating an immobilized 'sandwich'. A chemiluminescent substrate is then added which produces a light signal proportional to the concentration of PSA in the sample. Like immunoassays from other manufacturers using mouse monoclonal antibodies, the assay reagent contains mouse monoclonal immunoglobulins designed to block potential interferences from heterophilic antibodies. [10] [11] [12] [13] [14] The Beckman Hybritech assay (Beckman Coulter) is the most commonly used PSA assay according to the latest College of American Pathologists proficiency testing survey. Among 42400 laboratories, 27% used Beckman reagents with the next most common PSA assay used by 18% of labs. 15 When interpreting PSA results from any assay, intra-individual PSA variation must be taken into account. In healthy men with low PSA concentrations, a change of 30% between serial PSA measurements is considered significant. However, given the higher variability of serum PSA in men with prostate cancer, a change of 50-60% is considered significant. The results of all PSA tests performed in the VUMC Core Laboratory were acquired from the VUMC laboratory information system. All PSA results p1.0 ng ml À1 reported between 27 October 2008 and 26 October 2010 were reviewed (n ¼ 17 133; Figure 2 ). The Beckman Access Hybritech PSA reagent lots with reported increased susceptibility to heterophilic antibody interference were likely in use in the VUMC laboratory from April 2010 through October 2010. Thus, PSA results were queried approximately 18 months before and the 6 months during the use of the reagent in question. Patients with two or more PSA results during this time period were selected for further evaluation (n ¼ 8780 tests from 3706 patients). Finally, patients were included in our analysis if their PSA value was at any point undetectable (o0.1 ng ml
À1
) and then changed to a low, ). To detect all possible cases of spurious results, patients with any transient PSA elevation (from undetectable to detectable, and then back to undetectable), in the absence of adjuvant or salvage treatment, were deemed to have a spuriously elevated PSA. Clinical history was reviewed to determine whether patients had a history of prostate cancer. Demographic information and tumor characteristics were collected for each patient and any treatments resulting from the elevated PSA were recorded.
Phase II: prospective identification of suspicious PSA elevations and re-testing for heterophilic antibodies All PSA tests p0.5 ng ml À1 between 24 October 2010 and 19 January 2011 were prospectively reviewed on a daily basis (n ¼ 1288; Figure 3 ). Any PSA value that changed from an undetectable to a detectable level p0.5 ng ml À1 was flagged for further evaluation. This cutoff value was chosen to identify all spuriously elevated PSA values similar to those reported by Mayo Clinic. A chart review was performed to examine the clinical scenario surrounding the PSA result for each flagged patient. The PSA assay was then repeated with and without heterophilic antibody-blocking reagent. Reversion to undetectable PSA in the presence of the heterophilic antibodyblocking reagent suggested a falsely elevated PSA secondary to heterophilic antibodies. If the repeat assay confirmed the initial value, the PSA was considered to be truly elevated. Demographic information and tumor characteristics, for those with a prostate cancer history, were collected for each patient.
Heterophile blocking
For all samples identified in Phase II of the study, PSA analysis was repeated after incubating 500 ml serum in a control tube (untreated) and in a heterophilic antibodyblocking tube containing heterophilic antibody-blocking reagent (Scantibodies, Santee, CA, USA) for 1 h at room temperature. This procedure was also performed on several patient samples with no suspicion of heterophilic antibody interference to act as controls. The presence of heterophilic antibodies was confirmed if there was a ± 20% difference between the PSA results from the heterophilic antibody-blocking tube and untreated tubes. This difference reflects 2.8 times the running coefficient of variation for the PSA assay, which is 7.3% at the low end of the analytical range. Thus, any change greater than 20% is likely due to heterophilic antibody blocking and not assay variance. 16 
Outcome
We determined whether patients that had previously been treated for prostate cancer and were found to have a change from an undetectable to a detectable PSA went on to (a) a second PSA to confirm the result; (b) a period of observation; or (c) further diagnostic evaluation or salvage therapy.
Results

Phase I
After reviewing 17 133 consecutive PSA measurements in a retrospective fashion over a 2-year period, we identified 110 patients that previously had an undetectable PSA, who developed detectable values. Of these, 81 were either being treated for or diagnosed with recurrent prostate cancer; 17 did not yet have a repeat PSA (of whom 10 had a history of prostate cancer and ) after treatment for their cancer and was then found to have a detectable value. All 11 patients had their PSA rechecked within 3-6 months of elevation and all were found to again be undetectable. The mean value of the PSA elevation was 0.33±0.28 ng ml À1 (minimum 0.11 ng ml À1 , maximum 0.84 ng ml À1 ) and was transient in every patient. The PSA elevation occurred at a mean of 3.4±5.5 years post-treatment. Of the spuriously elevated PSA values, four were measured during the time period when the presumed defective reagent was used, and seven were not. Clinically, the spurious PSA elevation did not lead to unnecessary imaging or treatment in any patient.
Phase II
We reviewed 1288 PSA tests over a 3-month period and identified 10 patients with elevated PSA values (0.1-0.5 ng ml À1 ), who previously had undetectable values. Nine patients had a history of prostate cancer (Table 1) and most had intermediate-to high-risk disease, as evidenced by the significant proportion of patients with extracapsular extension, positive surgical margins and pathological T3 disease. One man had incomplete data on clinical stage, another had unknown pathological Gleason score. Each patient's PSA was repeated with and without a heterophilic antibody-blocking reagent. The PSA level remained elevated in each of these 10 cases, both with and without the blocking reagent ( Table 2 ). The mean change in percent PSA with and without heterophilic-blocking reagent was 5% (range: À15.8 to 3.7%) indicating the absence of interfering heterophilic antibodies and true PSA elevations in all cases. All patients with a history of prostate cancer were subsequently diagnosed with biochemical recurrent disease and treated accordingly. Spurious elevation of serum PSA CB Anderson et al
Discussion
In Phase I of a large quality improvement study, we estimated a 0.3% prevalence of a single, spuriously elevated PSA in our patient population. All spuriously elevated PSA values were greater than the expected assay variance, indicating they were significant elevations. Each patient identified with a spurious PSA retrospectively had a history of prostate cancer, but none went on to aggressive treatment or unnecessary diagnostic evaluation. In Phase II, 10 patients with a newly elevated PSA tested negative for heterophilic antibodies. This verified the absence of interfering heterophilic antibodies as the cause of the PSA elevation and suggested biochemical recurrent cancer in those men with a prostate cancer history. However, because heterophilic antibody interference is such a rare event, a much larger prospective study would be required to identify such an occurrence. Heterophilic antibodies are human immunoglobulins directed against various animal antigens, such as antigoat, anti-rabbit, and most commonly anti-mouse, and have been known to interfere with immunoassay tests as early as the 1980s. 17 They have a general prevalence between 0.2-40% and an estimated 1% prevalence in PSA assays. 3, 18 Commonly used immunoassays utilize animal antibodies, often monoclonal mouse antibodies, to recognize and quantify analytes. 4 Heterophilic antibodies can cause false positive, or rarely false negative, immunoassay results due to interference with the test by crossbinding the assay antibodies. 19 Inaccurate results for several different serum tests, [20] [21] [22] [23] [24] including human chorionic growth hormone, 25 troponin, 26 alpha fetoprotein 27 and PSA have all been reported, and in some cases, have led to unnecessary treatment. Heterophilic antibodies may cause various magnitudes and durations of inaccurate test results, depending on the antibody titer and strength. 19 Although we did not detect them in our prospective cohort and did not test for them in our retrospective cohort, the short, low-magnitude, spurious elevations of PSA may have been secondary to low-titer, transiently present heterophilic antibodies.
Several case reports describe heterophilic antibody interference with PSA immunoassay tests. Significantly elevated screening PSA values, as high as 83 ng ml À1 , 3, 7 and both persistent 5, 6, 8 and late PSA elevations 4,9 after radical prostatectomy have been reported. The majority of these reports describe chronic PSA elevations for several months, where the PSA would often be elevated by one assay, but undetectable when measured by another. Many of these false-positive PSA values resulted in unnecessary salvage treatment 3, 4, 6, 9 or led to an unnecessary metastatic workup. 5, 8 There is only one report of interfering heterophilic antibodies being discovered before unnecessary imaging or treatment. 7 Clearly, interfering heterophilic antibodies can have significant clinical consequences if not identified.
Leibowitz and Oh 28 reported a case of a persistently elevated PSA (430 ng ml À1 ) after radical prostatectomy that was undetectable when measured with a different assay and failed to respond to androgen deprivation therapy. The patient's serum tested negative for heterophilic antibodies, and the PSA was eventually found to be undetectable on both assays. Although the magnitude of the PSA elevation in this report was larger than what we describe in our analysis, it does document an extreme example of a concerning PSA elevation ultimately found to be due to laboratory error without heterophilic antibody interference identified.
It is possible that some of the patients in our prospective cohort did, in fact, have heterophilic antibody interference as the cause of their elevated PSA results, despite testing negative. Antibody-blocking reagents may fail to block heterophilic antibodies if antibodies have significant polyclonality or substantial natural variability, either of which could lead to a falsely negative blocking test. 5 Conceivably, patients in middle Tennessee may have been exposed to a unique animal antigen that is not blocked by conventional heterophilic antibody-blocking reagents. Because of the natural variability in heterophilic antibodies, they can be difficult to identify and remain a challenge for laboratory technicians and physicians alike. 29 Alternatively, there are other sources of error that may contribute to inaccurate PSA readings in the preanalytical, analytical, and/or post-analytical phases of testing. 2 For instance, abnormal test results may occur if serum is not stored or centrifuged properly, if the detection assay is not accurately calibrated, or if serum is obtained after manipulation of the prostate. Additionally, because there are differences between different PSA assays, patients should be followed using the same assay to eliminate a source of analytical error. Finally, studies have shown that in patients with prostatic disease, there can be a 20-60% variability between PSA measurements. 2, 30 Due to these potential sources of error, it is important to adhere to the National Academy of Clinical Biochemistry guidelines for the measurement of tumor markers. 2 These guidelines recommend that laboratories be aware of the possibility of analytical interferences, and that assay interferences should be considered whenever a tumor marker result does not agree with a patient's clinical picture. This necessitates the need for open communication between clinical and laboratory staff to identify aberrant results.
At the Mayo Clinic, medical directors in the clinical laboratory undertook a root cause analysis to determine if several elevated PSA results in post-prostatectomy patients without evidence of recurrent or metastatic disease were due to interfering heterophilic antibodies (personal communication). The elevated PSA results were traced to specific lots of Beckman Access Hybritech PSA reagent. Although the PSA assay reagent contains antibodies to block any heterophilic antibodies, a recent change in the reagent, such as the concentration or source of the blocking antibodies, may have affected the reagent's blocking capacity. After being notified of this problem, Beckman performed testing on suspicious reagents and found that all PSA reagent lots passed internal specifications. Customers were warned not to use a single PSA result to predict prostate cancer recurrence (personal communication).
As the purpose of our study was for quality improvement, we failed to identify a single patient that underwent unnecessary tests or treatment due to spurious PSA elevation. Although this is not always the case, as evidenced by prior reports, it confirms the value of the current recommendations for the definition of postprostatectomy biochemical recurrence, two successive PSA values X0.2 ng ml À1 . 31 If it had been determined This study does have limitations. It is partially retrospective, and it is possible that some patients went on to receive additional treatment for presumed biochemical cancer that had a falsely elevated PSA, but were not identified. Also, as this analysis only included PSA results p1.0 ng ml
À1
; any false elevations 41.0 ng ml
were not evaluated. Regardless, after analysis of 417 000 PSA measurements at a single institution, we estimate the prevalence of a spuriously elevated PSA to be approximately 0.3%. This did not lead to unnecessary treatment in any man with a history of prostate cancer. No patient in our prospective cohort tested positive for heterophilic antibody interference, pointing to the cause of their PSA elevation as either an unblocked interfering substance, such as heterophilic antibodies, or biochemically recurrent cancer, likely the latter. We recommend adhering to the current recommendations for the diagnosis of biochemically recurrent disease by confirming newly detectable PSA values in post-prostatectomy patients. If suspicious values do not fit a patient's clinical picture, laboratory staff should be contacted to test for the presence of heterophilic antibodies or other analytical error.
Conclusion
In a large cohort of patients, we estimate the prevalence of spuriously elevated PSA values 0.3%. Furthermore, out of 10 patients with spurious PSA elevations prospectively evaluated, none had evidence of interfering heterophilic antibodies. No patient in our series was subjected to unnecessary diagnostic evaluation or treatment. When using PSA for post-prostatectomy surveillance, it is crucial to confirm concerning values and always consider the presence of heterophilic antibodies if the PSA value does not correlate with the clinical scenario.
